Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis

Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.

Michael R. Grunwald, MD, FACP, hematologist/ oncologist, chief, Leukemia Division; director, Transplantation and Cellular Therapy Program, Levine Cancer Institute, Atrium Health, discusses the rates and incidence of disease progression in patients with low-risk myelofibrosis who were enrolled in the prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST; NCT02953704).